1 items1 sources3 stocks
The Motley Fool-Nov 15, 06:19 PM
Which Healthcare ETF Is the Better Buy: State Street’s Pharma Fund XPH or iShares’ Biotech Fund IBB?
The article compares XPH and IBB, noting that the funds differ in subsector focus, asset size, and cost structure. [[fact:fact-rju1jhej1]] XPH tracks mature pharmaceutical companies, while IBB focuses on biotechnology. [[fact:fact-bkg9jmu8t]] XPH's annual fee is 0.09 percentage points lower than IBB's, and it provides a higher trailing payout. [[fact:fact-cu5npfznx]] The author recommends XPH, arguing that drug-industry buyouts are active and XPH could benefit. [[fact:fact-7pzb2x97s]]